Merck announced that the U.S. FDA has granted Breakthrough Therapy Designation to KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer. This is the third Breakthrough Therapy Designation granted for KEYTRUDA.  KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Last month the U.S FDA approved Keytruda to treat patients suffering with advance non-small cell lung cancer (NSCLC).


Source:

http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-breakthrough-therapy-designation-us-food-and-